220 related articles for article (PubMed ID: 31932846)
1. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
2. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
3. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
5. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
7. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
[TBL] [Abstract][Full Text] [Related]
8. Donor
Schetelig J; Baldauf H; Heidenreich F; Hoogenboom JD; Spellman SR; Kulagin A; Schroeder T; Sengeloev H; Dreger P; Forcade E; Vydra J; Wagner-Drouet EM; Choi G; Paneesha S; Miranda NAA; Tanase A; de Wreede LC; Lange V; Schmidt AH; Sauter J; Fein JA; Bolon YT; He M; Marsh SGE; Gadalla SM; Paczesny S; Ruggeri A; Chabannon C; Fleischhauer K
Front Immunol; 2024; 15():1350470. PubMed ID: 38629074
[TBL] [Abstract][Full Text] [Related]
9. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
10. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg KJ; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1589-96. PubMed ID: 25960307
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
12. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
[TBL] [Abstract][Full Text] [Related]
14. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
[TBL] [Abstract][Full Text] [Related]
15. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
16. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
17. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
[TBL] [Abstract][Full Text] [Related]
18. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
[TBL] [Abstract][Full Text] [Related]
19. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
[TBL] [Abstract][Full Text] [Related]
20. Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients.
Escudero A; Martínez-Romera I; Fernández L; Valentín J; González-Vicent M; Vicario JL; Madero-Jarabo R; Diaz MÁ; Pérez-Martínez A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2493-2500. PubMed ID: 30145228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
